How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

Area of Science:

• Hematology
• Oncology
• Neurology

Background:

• Secondary central nervous system (CNS) relapse in aggressive non-Hodgkin lymphoma (NHL) carries a poor prognosis.
• While CNS relapse prophylaxis is standard for highly aggressive NHLs like Burkitt lymphoma, its use in diffuse large B-cell lymphoma (DLBCL) is debated due to a lower inherent risk.
• Identifying DLBCL patients who would benefit from CNS relapse prophylaxis remains a clinical challenge.

Purpose of the Study:

• To review current prognostic models and risk factors for CNS relapse in DLBCL.
• To discuss available prophylaxis methods for CNS relapse prevention in DLBCL.
• To provide a practical framework for managing CNS relapse risk in DLBCL patients.

Main Methods:

• Literature review of prognostic models for CNS relapse in DLBCL.
• Analysis of identified risk factors associated with CNS relapse in DLBCL.
• Evaluation of current strategies for CNS prophylaxis in DLBCL.

Main Results:

• Conflicting results exist among studies attempting to define high-risk DLBCL patients for CNS relapse.
• Several prognostic models and risk factors have been proposed but lack universal consensus.
• The optimal approach to CNS prophylaxis in DLBCL remains under investigation.

Conclusions:

• Defining high-risk DLBCL patients for CNS relapse requires careful consideration of multiple factors.
• A practical, evidence-based approach is needed to guide prophylaxis decisions.
• Further research is warranted to refine risk stratification and optimize CNS relapse prevention strategies in DLBCL.